Teladoc Health (NYSE:TDOC) Price Target Lowered to $10.00 at Deutsche Bank Aktiengesellschaft

Teladoc Health (NYSE:TDOC) had its price target trimmed by Deutsche Bank Aktiengesellschaft from $15.00 to $10.00 in a report published on Friday, Benzinga reports. The brokerage currently has a hold rating on the health services provider’s stock.

TDOC has been the subject of a number of other research reports. Canaccord Genuity Group reduced their price target on Teladoc Health from $25.00 to $17.00 and set a buy rating for the company in a report on Thursday, August 1st. TD Cowen cut their price objective on Teladoc Health from $15.00 to $9.00 and set a hold rating for the company in a research note on Thursday, August 1st. Truist Financial cut their price objective on Teladoc Health from $15.00 to $10.00 and set a hold rating for the company in a research note on Friday. JPMorgan Chase & Co. cut their price objective on Teladoc Health from $19.00 to $16.00 and set a neutral rating for the company in a research note on Tuesday, May 21st. Finally, Barclays cut their price objective on Teladoc Health from $20.00 to $10.00 and set an overweight rating for the company in a research note on Thursday, August 1st. Fourteen investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Hold and a consensus price target of $13.56.

Teladoc Health Price Performance

NYSE TDOC traded down $0.13 during trading hours on Friday, reaching $7.47. The company’s stock had a trading volume of 3,513,032 shares, compared to its average volume of 5,470,642. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -5.39 and a beta of 0.93. Teladoc Health has a 1-year low of $7.31 and a 1-year high of $26.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.82 and a quick ratio of 3.74. The company’s 50-day moving average is $9.81 and its two-hundred day moving average is $13.52.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, CEO Laizer Kornwasser sold 10,879 shares of Teladoc Health stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the sale, the chief executive officer now owns 99,929 shares in the company, valued at $813,422.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Karen L. Daniel sold 9,834 shares of Teladoc Health stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $11.90, for a total value of $117,024.60. Following the completion of the sale, the director now directly owns 36,995 shares of the company’s stock, valued at $440,240.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the transaction, the chief executive officer now directly owns 99,929 shares in the company, valued at approximately $813,422.06. The disclosure for this sale can be found here. Insiders have sold 36,177 shares of company stock worth $347,447 over the last quarter. 0.95% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Teladoc Health by 25.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock valued at $82,636,000 after purchasing an additional 767,999 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Teladoc Health by 6.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,654,116 shares of the health services provider’s stock worth $35,646,000 after purchasing an additional 104,531 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Teladoc Health by 1.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 916,129 shares of the health services provider’s stock worth $8,960,000 after purchasing an additional 14,910 shares during the period. Finally, Allianz Asset Management GmbH boosted its stake in shares of Teladoc Health by 15.4% in the 4th quarter. Allianz Asset Management GmbH now owns 604,238 shares of the health services provider’s stock valued at $13,021,000 after buying an additional 80,805 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.